OREANDA-NEWS. Faron Pharmaceuticals Ltd (LON: FARN), the clinical stage biopharmaceutical company, announces today that Markku Jalkanen, Chief Executive Officer, is scheduled to present at the Proactive Investors One2One Forum on Wednesday 22 June 2016 at 6:00pm in London.

The event will be held at Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB from 6:00pm to 8:00pm, followed by a drinks reception.

This event is open to private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


About Faron Pharmaceuticals Ltd 

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat Acute Respiratory Distress Syndrome ("ARDS"), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen®. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach called TIET (Tumour Immunity Enabling Technology). Faron Pharmaceuticals Ltd is listed on AIM under the ticker 'FARN'.